ursolic acid has been researched along with Pancreatic Neoplasms in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 4 (40.00) | 2.80 |
Authors | Studies |
---|---|
Jing, Y; Leal, AS; Salvador, JA; Wang, R | 2 |
Chun, KH; Kim, J; Kim, Y; Lim, JW; Yoon, Y | 1 |
Awale, S; Dibwe, DF; Kim, MJ; Omar, AM; Sun, S; Tawila, AM; Toyooka, N; Ueda, JY | 1 |
Gubernator, J; Jaromin, A; Markowski, A; Migdał, P; Olczak, E; Pawlik, K; Zaremba-Czogalla, M; Zygmunt, A | 1 |
Chen, SY; Li, ZY; Weng, MH; Yen, GC | 1 |
Chen, SY; Lin, JA; Lin, JH; Lu, CC; Yen, GC | 1 |
Aggarwal, BB; Gupta, SC; Prasad, S; Sung, B; Tyagi, AK; Yadav, VR | 1 |
Li, J; Liang, X; Yang, X | 1 |
Chadalapaka, G; Jutooru, I; McAlees, A; Safe, S; Stefanac, T | 1 |
10 other study(ies) available for ursolic acid and Pancreatic Neoplasms
Article | Year |
---|---|
Synthesis of novel ursolic acid heterocyclic derivatives with improved abilities of antiproliferation and induction of p53, p21waf1 and NOXA in pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Suppressor Protein p53; Ursolic Acid | 2012 |
Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in vivo antitumor effects in PANC-1 pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Humans; Mice, SCID; Pancreas; Pancreatic Neoplasms; Prodrugs; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
Chemical constituents of Callistemon citrinus from Egypt and their antiausterity activity against PANC-1 human pancreatic cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Egypt; Humans; Molecular Structure; Myrtaceae; Pancreatic Neoplasms; Structure-Activity Relationship; Terpenes; Tumor Microenvironment | 2020 |
Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Humans; Lactic Acid; Liposomes; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Triterpenes; Ursolic Acid | 2022 |
Ursolic acid restores sensitivity to gemcitabine through the RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse xenograft model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Triterpenes; Ursolic Acid | 2021 |
Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Humans; Pancreatic Neoplasms; Survival Rate; Triterpenes; Ursolic Acid | 2020 |
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inflammation; Mice; Mice, Nude; Pancreatic Neoplasms; Triterpenes; Tumor Microenvironment; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Nude; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Random Allocation; Signal Transduction; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2012 |
Semisynthetic ursolic acid fluorolactone derivatives inhibit growth with induction of p21(waf1) and induce apoptosis with upregulation of NOXA and downregulation of c-FLIP in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; G1 Phase; Halogenation; Humans; Lactones; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Up-Regulation; Ursolic Acid | 2012 |
Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives.
Topics: Cell Line, Tumor; Cell Proliferation; Glycyrrhetinic Acid; Humans; Methylation; Molecular Structure; Pancreatic Neoplasms; Structure-Activity Relationship; Triterpenes; Urinary Bladder Neoplasms; Ursolic Acid | 2008 |